US4996335A
(en)
|
1980-07-10 |
1991-02-26 |
Nicholas S. Bodor |
Soft steroids having anti-inflammatory activity
|
US4789724A
(en)
|
1986-10-17 |
1988-12-06 |
Massachusetts Institute Of Technology |
Preparation of anhydride copolymers
|
CA1325382C
(en)
|
1988-01-27 |
1993-12-21 |
Takahiro Ogawa |
Locally administrable therapeutic composition for inflammatory disease
|
US5442039A
(en)
|
1989-07-17 |
1995-08-15 |
The Dow Chemical Company |
Mesogenic polycyanates and thermosets thereof
|
US5190956A
(en)
|
1990-09-07 |
1993-03-02 |
Schering Corporation |
Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections
|
CZ281628B6
(cs)
|
1991-07-29 |
1996-11-13 |
Warner-Lambert Company |
Deriváty chinazolinu a farmaceutické přípravky na jejich bázi
|
US6235313B1
(en)
|
1992-04-24 |
2001-05-22 |
Brown University Research Foundation |
Bioadhesive microspheres and their use as drug delivery and imaging systems
|
US6197346B1
(en)
|
1992-04-24 |
2001-03-06 |
Brown Universtiy Research Foundation |
Bioadhesive microspheres and their use as drug delivery and imaging systems
|
NZ248813A
(en)
|
1992-11-25 |
1995-06-27 |
Eastman Kodak Co |
Polymeric grinding media used in grinding pharmaceutical substances
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
US5364884A
(en)
|
1993-01-21 |
1994-11-15 |
Baylor College Of Medicine |
Arginine compounds as ocular hypotensive agents
|
US5534259A
(en)
|
1993-07-08 |
1996-07-09 |
Liposome Technology, Inc. |
Polymer compound and coated particle composition
|
EP0712421A1
(en)
|
1993-07-23 |
1996-05-22 |
Massachusetts Institute Of Technology |
Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
|
US5540930A
(en)
|
1993-10-25 |
1996-07-30 |
Pharmos Corporation |
Suspension of loteprednol etabonate for ear, eye, or nose treatment
|
AU1702395A
(en)
|
1994-02-17 |
1995-09-04 |
Pankaj Modi |
Drugs, vaccines and hormones in polylactide coated microspheres
|
AU2096895A
(en)
|
1994-03-07 |
1995-09-25 |
Sugen, Incorporated |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
GB9406094D0
(en)
|
1994-03-28 |
1994-05-18 |
Univ Nottingham And University |
Polymer microspheres and a method of production thereof
|
TW384224B
(en)
|
1994-05-25 |
2000-03-11 |
Nano Sys Llc |
Method of preparing submicron particles of a therapeutic or diagnostic agent
|
US5718388A
(en)
|
1994-05-25 |
1998-02-17 |
Eastman Kodak |
Continuous method of grinding pharmaceutical substances
|
GB9514265D0
(en)
|
1995-07-13 |
1995-09-13 |
Wellcome Found |
Hetrocyclic compounds
|
WO1997020578A1
(en)
|
1995-12-04 |
1997-06-12 |
University Of Miami |
Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
|
US6046208A
(en)
|
1996-01-11 |
2000-04-04 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
US6106819A
(en)
|
1996-12-31 |
2000-08-22 |
Sucher; David F. |
Methods of treating headache and functional extraocular and intraocular myotendinitis
|
ZA9711732B
(en)
|
1996-12-31 |
1998-12-28 |
Quadrant Holdings Cambridge |
Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
|
EP1021414B1
(en)
|
1997-01-06 |
2003-06-18 |
Cerus Corporation |
Frangible compounds for pathogen inactivation
|
PT954282E
(pt)
|
1997-01-16 |
2005-06-30 |
Massachusetts Inst Technology |
Preparacao de particulas para inalacao
|
US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
GB9713980D0
(en)
|
1997-07-03 |
1997-09-10 |
Danbiosyst Uk |
New conjugates
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
FR2772763B1
(fr)
|
1997-12-24 |
2004-01-23 |
Sod Conseils Rech Applic |
Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
US6165509A
(en)
|
1998-09-01 |
2000-12-26 |
University Of Washington |
Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
CZ303899B6
(cs)
|
1998-09-29 |
2013-06-19 |
Wyeth Holdings Corporation |
Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
|
ATE294796T1
(de)
*
|
1998-10-08 |
2005-05-15 |
Astrazeneca Ab |
Chinazolin derivate
|
US6372246B1
(en)
|
1998-12-16 |
2002-04-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
|
BR0008590A
(pt)
|
1999-01-08 |
2001-10-30 |
Emisphere Tech Inc |
Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
|
GB2345486A
(en)
|
1999-01-11 |
2000-07-12 |
Glaxo Group Ltd |
Heteroaromatic protein tyrosine kinase inhibitors
|
EP1147094A1
(en)
|
1999-01-15 |
2001-10-24 |
Novo Nordisk A/S |
Non-peptide glp-1 agonists
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
US6355271B1
(en)
|
1999-02-03 |
2002-03-12 |
Biosante Pharmaceuticals, Inc. |
Therapeutic calcium phosphate particles and methods of manufacture and use
|
ES2351699T3
(es)
*
|
1999-02-10 |
2011-02-09 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores de la angiogénesis e intermedios de los mismos.
|
SK12112001A3
(sk)
|
1999-02-27 |
2001-12-03 |
Boehringer Ingelheim Pharma Kg |
4-amino-chinazolínové a chinolínové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
|
DE19911509A1
(de)
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6972296B2
(en)
|
1999-05-07 |
2005-12-06 |
Encysive Pharmaceuticals Inc. |
Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
US6264981B1
(en)
|
1999-10-27 |
2001-07-24 |
Anesta Corporation |
Oral transmucosal drug dosage using solid solution
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
AR035851A1
(es)
|
2000-03-28 |
2004-07-21 |
Wyeth Corp |
3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
|
WO2001074790A2
(en)
|
2000-03-30 |
2001-10-11 |
The Penn State Research Foundation |
Novel compounds for enhancing chemotherapy
|
GB0008269D0
(en)
|
2000-04-05 |
2000-05-24 |
Astrazeneca Ab |
Combination chemotherapy
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
CA2415469A1
(en)
|
2000-08-09 |
2002-02-14 |
Astrazeneca Ab |
Quinoline derivatives having vegf inhibiting activity
|
DE10042059A1
(de)
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
AP1666A
(en)
|
2000-09-11 |
2006-09-29 |
Chiron Corp |
Quinolinone derivatives as tyrosine kinase inhibitors.
|
FR2814167B1
(fr)
|
2000-09-15 |
2002-11-08 |
Aventis Pharma Sa |
Preparation de la camptothecine et de ses derives
|
EP1332134A2
(en)
|
2000-10-25 |
2003-08-06 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
ES2382636T3
(es)
|
2000-10-31 |
2012-06-12 |
Surmodics Pharmaceuticals, Inc. |
Método para producir composiciones para la administración mejorada de moléculas bioactivas
|
GB0027357D0
(en)
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
GB2370839A
(en)
|
2001-01-06 |
2002-07-10 |
Benedikt Timmerman |
Immunogenic complex useful for disease control
|
US6855720B2
(en)
|
2001-03-01 |
2005-02-15 |
California Pacific Medical Center |
Nitrogen-based camptothecin derivatives
|
US20030125344A1
(en)
|
2001-03-23 |
2003-07-03 |
Bayer Corporation |
Rho-kinase inhibitors
|
US7141577B2
(en)
*
|
2001-04-19 |
2006-11-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO2002088079A2
(en)
|
2001-05-01 |
2002-11-07 |
Bristol-Myers Squibb Company |
Dual inhibitors of pde 7 and pde 4
|
SE0101675D0
(sv)
|
2001-05-11 |
2001-05-11 |
Astrazeneca Ab |
Novel composition
|
DE10128110A1
(de)
|
2001-06-11 |
2003-01-02 |
Univ Hannover |
Verbindungen zum Anlagern an Nucleinsäuren
|
PE20030008A1
(es)
|
2001-06-19 |
2003-01-22 |
Bristol Myers Squibb Co |
Inhibidores duales de pde 7 y pde 4
|
EP1408971A4
(en)
|
2001-06-21 |
2006-01-25 |
Ariad Pharma Inc |
NEW QUINOLINES AND THEIR USES
|
EP1408980A4
(en)
|
2001-06-21 |
2004-10-20 |
Ariad Pharma Inc |
NEW QUINAZOLINES AND THEIR USE
|
US7163697B2
(en)
|
2001-06-22 |
2007-01-16 |
Johns Hopkins University School Of Medicine |
Biodegradable polymer compositions, compositions and uses related thereto
|
US20050191359A1
(en)
|
2001-09-28 |
2005-09-01 |
Solubest Ltd. |
Water soluble nanoparticles and method for their production
|
EP1447405A4
(en)
|
2001-10-17 |
2005-01-12 |
Kirin Brewery |
QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
|
GB0126433D0
(en)
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
GB0128108D0
(en)
|
2001-11-23 |
2002-01-16 |
Astrazeneca Ab |
Therapeutic use
|
JP2005519876A
(ja)
|
2001-11-27 |
2005-07-07 |
メルク エンド カムパニー インコーポレーテッド |
2−アミノキノリン化合物
|
EP1451156A4
(en)
|
2001-11-27 |
2005-05-25 |
Merck & Co Inc |
4-AMINOQUINOLINE COMPOUNDS
|
AR037641A1
(es)
|
2001-12-05 |
2004-11-17 |
Tularik Inc |
Moduladores de inflamacion
|
EP1454898A4
(en)
|
2001-12-13 |
2006-12-13 |
Ajinomoto Kk |
NEW PHENYL ALANIDE DERIVATIVES
|
AU2002359694A1
(en)
|
2001-12-14 |
2003-06-30 |
Smithkline Beecham Corporation |
Compounds and methods
|
PL371486A1
(en)
*
|
2002-02-01 |
2005-06-13 |
Astrazeneca Ab |
Quinazoline compounds
|
CA2369970A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
US6822097B1
(en)
|
2002-02-07 |
2004-11-23 |
Amgen, Inc. |
Compounds and methods of uses
|
AU2006220411B2
(en)
|
2002-03-20 |
2008-06-26 |
Alkermes, Inc. |
Inhalable Sustained Therapeutic Formulations
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
AU2003241898A1
(en)
|
2002-06-03 |
2003-12-19 |
Mitsubishi Pharma Corporation |
PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
|
US20040033222A1
(en)
|
2002-08-14 |
2004-02-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Anticoagulant and fibrinolytic therapy uning p38 MAP kinase inhibitors
|
CA2496164C
(en)
|
2002-08-23 |
2010-11-09 |
Chiron Corporation |
Benzimidazole quinolinones and uses thereof
|
US20050256157A1
(en)
|
2002-08-23 |
2005-11-17 |
Chiron Corporation |
Combination therapy with CHK1 inhibitors
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
CA2500218A1
(en)
|
2002-09-26 |
2004-04-08 |
Yamanouchi Pharmaceutical Co., Ltd. |
Drug absorptivity improving agent
|
WO2004044046A2
(en)
|
2002-11-08 |
2004-05-27 |
Encysive Pharmaceuticals |
Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
|
US7488823B2
(en)
|
2003-11-10 |
2009-02-10 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
EP1567506A4
(en)
|
2002-11-20 |
2007-06-20 |
Array Biopharma Inc |
CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
|
EP1575966B1
(en)
|
2002-12-24 |
2008-10-29 |
AstraZeneca AB |
Therapeutic quinazoline derivatives
|
AU2003290322A1
(en)
|
2002-12-24 |
2004-07-22 |
Astrazeneca Ab |
Quinazoline compounds
|
MY136174A
(en)
|
2002-12-24 |
2008-08-29 |
Astrazeneca Ab |
Phosphonooxy quinazoline derivatives and their pharmaceutical use
|
JPWO2004060400A1
(ja)
|
2003-01-06 |
2006-05-11 |
那波 宏之 |
上皮成長因子受容体を分子標的とする抗精神病薬
|
US20040159900A1
(en)
*
|
2003-01-27 |
2004-08-19 |
3M Innovative Properties Company |
Phosphor based light sources having front illumination
|
US20050266090A1
(en)
|
2003-04-29 |
2005-12-01 |
Ales Prokop |
Nanoparticular targeting and therapy
|
WO2005044224A2
(en)
|
2003-05-02 |
2005-05-19 |
Case Western Reserve University |
Drug delivery system based on polymer nanoshells
|
DK1638941T3
(da)
|
2003-05-22 |
2010-10-11 |
Abbott Lab |
Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
|
WO2004105809A1
(en)
|
2003-05-22 |
2004-12-09 |
Elan Pharma International Ltd. |
Sterilization of dispersions of nanoparticulate active agents with gamma radiation
|
US7727969B2
(en)
|
2003-06-06 |
2010-06-01 |
Massachusetts Institute Of Technology |
Controlled release nanoparticle having bound oligonucleotide for targeted delivery
|
DE10331500A1
(de)
|
2003-07-11 |
2005-02-24 |
Zentaris Gmbh |
Neue Acridin-Derivate und deren Verwendung als Arzneimittel
|
US20050009809A1
(en)
|
2003-07-11 |
2005-01-13 |
Matthias Gerlach |
Acridine derivatives and their use as medicaments
|
GB0318422D0
(en)
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
US20050124562A1
(en)
|
2003-09-23 |
2005-06-09 |
Joseph Guiles |
Bis-quinazoline compounds for the treatment of bacterial infections
|
WO2005035521A1
(en)
|
2003-10-09 |
2005-04-21 |
Argenta Discovery Ltd. |
Substituted quinolines as mcr modulators
|
KR101224410B1
(ko)
|
2003-11-07 |
2013-01-23 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
퀴놀리논 화합물을 합성하는 방법
|
UA82577C2
(en)
|
2003-12-23 |
2008-04-25 |
Пфайзер Инк. |
Quinoline derivatives
|
AU2005207946A1
(en)
*
|
2004-01-23 |
2005-08-11 |
Amgen Inc. |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
US7435823B2
(en)
|
2004-01-23 |
2008-10-14 |
Amgen Inc. |
Compounds and methods of use
|
WO2005072710A2
(en)
|
2004-01-28 |
2005-08-11 |
Johns Hopkins University |
Drugs and gene carrier particles that rapidly move through mucous barriers
|
SE0400284D0
(sv)
|
2004-02-10 |
2004-02-10 |
Astrazeneca Ab |
Novel compounds
|
EP1724268A4
(en)
|
2004-02-20 |
2010-04-21 |
Kirin Pharma Kk |
COMPOUND HAVING TGF-BETA INHIBITING ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
|
BRPI0507891A
(pt)
|
2004-02-20 |
2007-07-24 |
Chiron Corp |
modulação dos processos inflamatório e metastático
|
TW200529846A
(en)
|
2004-02-20 |
2005-09-16 |
Wyeth Corp |
3-quinolinecarbonitrile protein kinase inhibitors
|
AU2005219413A1
(en)
|
2004-03-02 |
2005-09-15 |
Massachusetts Institute Of Technology |
Nanocell drug delivery system
|
EP1744759B1
(en)
|
2004-03-25 |
2009-09-02 |
Bausch & Lomb Incorporated |
Use of loteprednol etabonate for the treatment of dry eye
|
WO2005097134A2
(en)
|
2004-03-31 |
2005-10-20 |
The Scripps Research Institute |
Quinazoline based protein kinase inhibitors
|
WO2005112938A2
(en)
|
2004-04-13 |
2005-12-01 |
Synta Pharmaceuticals Corp. |
Disalt inhibitors of il-12 production
|
AU2005329255B2
(en)
|
2004-04-15 |
2010-09-30 |
Chiasma, Inc. |
Compositions capable of facilitating penetration across a biological barrier
|
ES2246694B1
(es)
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
EP1755680A1
(en)
|
2004-05-03 |
2007-02-28 |
Novartis AG |
Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
|
US20100226931A1
(en)
|
2004-06-24 |
2010-09-09 |
Nicholas Valiante |
Compounds for immunopotentiation
|
JP2008512350A
(ja)
|
2004-07-01 |
2008-04-24 |
イェール ユニバーシティ |
標的化され、そして高密度で薬物が負荷されるポリマー性物質
|
CA2573103A1
(en)
|
2004-07-06 |
2006-02-09 |
Angion Biomedica Corporation |
Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
|
WO2006030947A1
(ja)
|
2004-09-13 |
2006-03-23 |
Eisai R & D Management Co., Ltd. |
スルホンアミド含有化合物の血管新生阻害物質との併用
|
US8653055B2
(en)
|
2004-09-15 |
2014-02-18 |
Teva Animal Health, Inc. |
Corticosteroid having low systemic absorption
|
CA2579067A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Astrazeneca Ab |
Cancer combination therapy comprising azd2171 and imatinib
|
US20070054916A1
(en)
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
JP5682991B2
(ja)
|
2004-10-01 |
2015-03-11 |
ラムズコア, インコーポレイテッド |
便利に移植可能な徐放性薬物処方物
|
TW200616612A
(en)
|
2004-10-08 |
2006-06-01 |
Wyeth Corp |
Method for the teatment of polycystic kidney disease field of invention
|
EP1802608A1
(en)
*
|
2004-10-12 |
2007-07-04 |
AstraZeneca AB |
Quinazoline derivatives for use against cancer
|
US20060083781A1
(en)
|
2004-10-14 |
2006-04-20 |
Shastri V P |
Functionalized solid lipid nanoparticles and methods of making and using same
|
ES2450566T3
(es)
|
2004-11-30 |
2014-03-25 |
Amgen Inc. |
Análogos de quinazolina y quinolinas y su uso como medicamentos para tratar el cáncer
|
EP1856179B1
(en)
|
2004-12-10 |
2013-05-15 |
Kala Pharmaceuticals, Inc. |
Functionalized poly (ether-anhydride) block copolymers
|
JP2008530239A
(ja)
|
2005-02-18 |
2008-08-07 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド |
アルデスロイキンを含む抗血管形成性剤
|
TW200640443A
(en)
|
2005-02-23 |
2006-12-01 |
Alcon Inc |
Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
|
DE102005009705A1
(de)
|
2005-03-03 |
2006-09-07 |
Universität des Saarlandes |
Selektive Hemmstoffe humaner Corticoidsynthasen
|
US9271963B2
(en)
|
2005-03-03 |
2016-03-01 |
Universitat Des Saarlandes |
Selective inhibitors of human corticosteroid synthases
|
DE102005011786A1
(de)
|
2005-03-11 |
2006-09-14 |
Pharmasol Gmbh |
Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
|
US8048889B2
(en)
|
2005-03-29 |
2011-11-01 |
Xtl Biopharmaceuticals Ltd. |
3,4-disubstituted coumarin and quinolone compounds
|
DK1868998T3
(en)
|
2005-04-01 |
2016-08-29 |
Vfp Therapies |
NEW HETEROCYCLIC COMPOUNDS, MANUFACTURING THEM, AND USE THEREOF AS MEDICINES, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
GB0509224D0
(en)
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Inhibitors of intracellular enzymatic activity
|
GB0509227D0
(en)
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Intracellular enzyme inhibitors
|
ZA200709251B
(en)
|
2005-05-10 |
2009-08-26 |
Alcon Inc |
Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
|
CA2608540A1
(en)
|
2005-05-18 |
2006-11-23 |
Wyeth |
3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
|
CN101180269A
(zh)
|
2005-05-25 |
2008-05-14 |
惠氏公司 |
制备3-氰基-喹啉的方法和由其制得的中间体
|
RU2007143161A
(ru)
|
2005-05-25 |
2009-07-10 |
Вайет (Us) |
Способы синтеза замещенных 3-цианохинов и их продуктов
|
CN1313449C
(zh)
|
2005-07-14 |
2007-05-02 |
沈阳中海生物技术开发有限公司 |
新的喹唑啉类衍生物、含有其的药物组合物以及它们的用途
|
JP5066446B2
(ja)
|
2005-08-01 |
2012-11-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を予測する方法
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
FR2889527A1
(fr)
|
2005-08-05 |
2007-02-09 |
Servier Lab |
Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
JP4792262B2
(ja)
|
2005-09-09 |
2011-10-12 |
富士フイルム株式会社 |
有機電界発光素子及び錯体化合物
|
WO2007033196A1
(en)
|
2005-09-14 |
2007-03-22 |
Bristol-Myers Squibb Company |
Met kinase inhibitors
|
CA2623293A1
(en)
|
2005-09-20 |
2007-03-29 |
Shimon Benita |
Nanoparticles for targeted delivery of active agents
|
US7875602B2
(en)
|
2005-10-21 |
2011-01-25 |
Sutter West Bay Hospitals |
Camptothecin derivatives as chemoradiosensitizing agents
|
CN1955183B
(zh)
|
2005-10-28 |
2011-04-20 |
中国医学科学院药物研究所 |
20-位酯化的喜树碱衍生物、其制法和其药物组合物与用途
|
US20070149523A1
(en)
|
2005-11-14 |
2007-06-28 |
Jan Ehlert |
Thiazole Analogues and Uses Thereof
|
EP1785420A1
(en)
|
2005-11-14 |
2007-05-16 |
4Sc Ag |
Thiazole analogues and uses thereof
|
DK1962808T3
(da)
|
2005-12-14 |
2010-11-08 |
Hoffmann La Roche |
HCV prodrug-formulering
|
WO2007076448A2
(en)
|
2005-12-23 |
2007-07-05 |
Alcon, Inc. |
Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
|
US20080058312A1
(en)
|
2006-01-11 |
2008-03-06 |
Angion Biomedica Corporation |
Modulators of hepatocyte growth factor/c-Met activity
|
US7977346B2
(en)
|
2006-01-17 |
2011-07-12 |
Guoqing Paul Chen |
Spiro compounds and methods of use
|
US20070196860A1
(en)
|
2006-01-18 |
2007-08-23 |
Invitrogen Corporation |
Methods for Measuring Real Time Kinase Activity
|
US20070178051A1
(en)
|
2006-01-27 |
2007-08-02 |
Elan Pharma International, Ltd. |
Sterilized nanoparticulate glucocorticosteroid formulations
|
GB2444101A
(en)
|
2006-02-24 |
2008-05-28 |
Investigen Inc |
Methods and compositions for detecting polynucleotides
|
EP2010677A4
(en)
|
2006-02-24 |
2010-04-14 |
Investigen Inc |
METHODS AND COMPOSITIONS FOR DETECTION OF POLYNUCLEOTIDES
|
WO2007104696A1
(en)
|
2006-03-15 |
2007-09-20 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Antimalarial agents having polyaromatic structure
|
GB0605691D0
(en)
|
2006-03-21 |
2006-05-03 |
Novartis Ag |
Organic Compounds
|
JP5313867B2
(ja)
|
2006-03-30 |
2013-10-09 |
ドライス ファーマシューティカルズ,インコーポレイティド |
カンプトテシン−細胞透過性ペプチド複合体及びそれを含む医薬組成物
|
CN101466682A
(zh)
|
2006-04-14 |
2009-06-24 |
阿斯利康(瑞典)有限公司 |
作为csf-1r激酶抑制剂的4-苯胺基喹啉-3-甲酰胺
|
WO2007125405A2
(en)
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
WO2007133808A2
(en)
|
2006-05-15 |
2007-11-22 |
Liquidia Technologies, Inc. |
Nano-particles for cosmetic applications
|
JP2009537518A
(ja)
|
2006-05-15 |
2009-10-29 |
エックスティーエル バイオファーマシューティカルズ,リミテッド |
3,4−二置換クマリン及びキノロン化合物
|
US7691811B2
(en)
|
2006-05-25 |
2010-04-06 |
Bodor Nicholas S |
Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
|
US20110053931A1
(en)
|
2006-06-08 |
2011-03-03 |
John Gaudino |
Quinoline compounds and methods of use
|
WO2008001956A1
(fr)
|
2006-06-29 |
2008-01-03 |
Eisai R & D Management Co., Ltd. |
Agent thérapeutique contre la fibrose hépatique
|
WO2008006050A2
(en)
|
2006-07-07 |
2008-01-10 |
Govek Steven P |
Bicyclic heteroaryl inhibitors of pde4
|
WO2008020302A2
(en)
|
2006-08-17 |
2008-02-21 |
Pfizer Products Inc. |
Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
|
EP2061433B1
(en)
|
2006-09-08 |
2011-02-16 |
Johns Hopkins University |
Compositions for enhancing transport through mucus
|
CA2662587C
(en)
|
2006-09-11 |
2013-08-06 |
Curis, Inc. |
Quinazoline based egfr inhibitors
|
US8821943B2
(en)
|
2006-09-12 |
2014-09-02 |
Board Of Regents Of The University Of Nebraska |
Methods and compositions for targeted delivery of therapeutic agents
|
US20080096193A1
(en)
|
2006-10-24 |
2008-04-24 |
Charles Robert Bupp |
Methods and compositions for detecting polynucleotides
|
US7851623B2
(en)
|
2006-11-02 |
2010-12-14 |
Astrazeneca Ab |
Chemical process
|
TW200829555A
(en)
|
2006-11-10 |
2008-07-16 |
Astrazeneca Ab |
Chemical compounds
|
US8414909B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
CA2672440A1
(en)
|
2006-12-20 |
2008-07-03 |
Amgen Inc. |
Substituted heterocycles and methods of use
|
CN100540551C
(zh)
|
2007-02-01 |
2009-09-16 |
中国药科大学 |
喹啉衍生物、其制备方法及其医药用途
|
CN100540552C
(zh)
|
2007-02-01 |
2009-09-16 |
中国药科大学 |
3-氰基喹啉衍生物、其制备方法及其医药用途
|
US20080221161A1
(en)
|
2007-02-09 |
2008-09-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
EP2114898A2
(en)
|
2007-02-16 |
2009-11-11 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
|
JP2008214323A
(ja)
|
2007-03-08 |
2008-09-18 |
Kyowa Hakko Kogyo Co Ltd |
皮膚疾患の治療及び/または予防剤
|
WO2008112913A1
(en)
|
2007-03-14 |
2008-09-18 |
Exelixis, Inc. |
Inhibitors of the hedgehog pathway
|
US8148532B2
(en)
*
|
2007-03-14 |
2012-04-03 |
Guoqing Paul Chen |
Spiro substituted compounds as angiogenesis inhibitors
|
WO2008113161A1
(en)
|
2007-03-19 |
2008-09-25 |
Ulysses Pharmaceutical Products Inc. |
Phosphate prodrugs of quinazolinyl nitrofurans, methods of obtaining, and use of same
|
DE102007015169A1
(de)
|
2007-03-27 |
2008-10-02 |
Universität des Saarlandes Campus Saarbrücken |
17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
|
WO2008124639A2
(en)
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Poly (amino acid) targeting moieties
|
DE102007017654A1
(de)
|
2007-04-12 |
2008-10-16 |
Henkel Ag & Co. Kgaa |
Bis(hydroxychinolin)-Metallkomplexe als Bleichkatalysatoren
|
CN101317847B
(zh)
|
2007-06-06 |
2010-10-13 |
深圳市瑞谷医药技术有限公司 |
一种眼用或耳鼻用药物组合物及其用途
|
US7928111B2
(en)
|
2007-06-08 |
2011-04-19 |
Senomyx, Inc. |
Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
|
AR067027A1
(es)
|
2007-06-19 |
2009-09-30 |
Astrazeneca Ab |
Derivados de 2, 3-dihidro-1h-pirrol[3, 4b]quinolin-1-ona, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la modulacion de la actividad del receptor gaba a.
|
WO2009014730A1
(en)
|
2007-07-26 |
2009-01-29 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
CA2708319A1
(en)
|
2007-07-27 |
2009-02-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Supramolecular functionalization of graphitic nanoparticles for drug delivery
|
WO2009017838A2
(en)
*
|
2007-08-01 |
2009-02-05 |
Exelixis, Inc. |
Combinations of jak-2 inhibitors and other agents
|
CN101108846B
(zh)
|
2007-08-10 |
2011-02-09 |
东南大学 |
4-芳香氨基喹唑啉衍生物及制备方法和在制药中的应用
|
US20090062337A1
(en)
|
2007-08-31 |
2009-03-05 |
Wysis Technology Foundation, Inc. |
Treatment of Microbial Infections
|
DE102008012435A1
(de)
*
|
2008-02-29 |
2009-09-03 |
Schebo Biotech Ag |
Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie
|
WO2009030224A2
(de)
|
2007-09-07 |
2009-03-12 |
Schebo Biotech Ag |
Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
|
TW200922590A
(en)
|
2007-09-10 |
2009-06-01 |
Curis Inc |
VEGFR inhibitors containing a zinc binding moiety
|
EP2205076A4
(en)
|
2007-09-24 |
2010-12-29 |
Tragara Pharmaceuticals Inc |
POLYTHERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DOUBLE INHIBITORS OF EGFR ÝERBB1 AND HER-2 ÝERBB2
|
ATE554076T1
(de)
|
2008-01-17 |
2012-05-15 |
Bayer Pharma AG |
Sulfoximinsubstituierte chinazolinderivate als immunmodulatoren, ihre herstellung und ihre verwendung als medikamente
|
WO2009094211A1
(en)
|
2008-01-22 |
2009-07-30 |
Concert Pharmaceuticals Inc. |
Quinazoline compounds and methods of treating cancer
|
WO2009108905A2
(en)
|
2008-02-28 |
2009-09-03 |
Life Technologies Corporation |
Fluorescence polarization herg assay
|
CN101239978A
(zh)
|
2008-03-05 |
2008-08-13 |
南方医科大学 |
一种咪唑并吡啶类化合物
|
WO2009126691A1
(en)
|
2008-04-09 |
2009-10-15 |
Infinity Pharmaceuticals, Inc |
Inhibitors of fatty acid amide hydrolase
|
CN102056927B
(zh)
*
|
2008-05-13 |
2014-06-25 |
Irm责任有限公司 |
作为激酶抑制剂的稠合含氮杂环及其组合物
|
MX2010012290A
(es)
|
2008-05-14 |
2011-02-21 |
Amgen Inc |
Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.
|
EP2149565A1
(de)
|
2008-07-24 |
2010-02-03 |
Bayer Schering Pharma AG |
Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
|
US8211911B2
(en)
*
|
2008-08-19 |
2012-07-03 |
Guoqing Paul Chen |
Compounds as kinase inhibitors
|
TWI580441B
(zh)
|
2008-09-19 |
2017-05-01 |
愛爾康研究有限公司 |
穩定的藥學次微米懸浮液及其形成方法
|
JP5734193B2
(ja)
|
2008-10-14 |
2015-06-17 |
クイ ニング |
化合物及び使用方法
|
JP2012506436A
(ja)
|
2008-10-22 |
2012-03-15 |
ハウス イアー インスティトゥート |
代謝型グルタミン酸受容体の調節による内耳の疾病の処置および/または予防
|
WO2010056758A1
(en)
|
2008-11-12 |
2010-05-20 |
Yangbo Feng |
Quinazoline derivatives as kinase inhibitors
|
CN101747306B
(zh)
|
2008-11-28 |
2012-08-29 |
中国中化股份有限公司 |
取代醚类化合物及其应用
|
JP5471063B2
(ja)
|
2009-02-23 |
2014-04-16 |
住友化学株式会社 |
環状化合物、その金属錯体及び変性金属錯体
|
TWI461197B
(zh)
|
2009-03-12 |
2014-11-21 |
|
2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
|
CA2755251A1
(en)
|
2009-03-18 |
2010-09-23 |
Schering Corporation |
Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
|
US10952965B2
(en)
|
2009-05-15 |
2021-03-23 |
Baxter International Inc. |
Compositions and methods for drug delivery
|
US9241928B2
(en)
|
2009-06-26 |
2016-01-26 |
The General Hospital Corporation |
Antimicrobial compounds
|
SG179085A1
(en)
*
|
2009-09-09 |
2012-04-27 |
Avila Therapeutics Inc |
Pi3 kinase inhibitors and uses thereof
|
JP5827627B2
(ja)
|
2009-11-07 |
2015-12-02 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
TGF−β受容体キナーゼ阻害剤としてのヘテロアリールアミノキノリン
|
CN102086211B
(zh)
*
|
2009-12-08 |
2013-09-11 |
广东东阳光药业有限公司 |
作为蛋白激酶抑制剂的芳杂环化合物
|
EP2335686A1
(en)
|
2009-12-21 |
2011-06-22 |
LEK Pharmaceuticals d.d. |
An aqueous intravenous nanosuspension with reduced adverse effects
|
DE102010006121B4
(de)
|
2010-01-29 |
2022-08-11 |
Merck Patent Gmbh |
Materialien für organische Elektrolumineszenzvorrichtungen
|
DE102010007938A1
(de)
|
2010-02-12 |
2011-10-06 |
Merck Patent Gmbh |
Elektrolumineszierende Polymere, Verfahren zu ihrer Herstellung sowie ihre Verwendung
|
WO2011106168A1
(en)
|
2010-02-24 |
2011-09-01 |
Dcam Pharma Inc |
Purine compounds for treating autoimmune and demyelinating diseases
|
CA2791278C
(en)
|
2010-02-25 |
2015-11-24 |
The Johns Hopkins University |
Sustained delivery of therapeutic agents to an eye compartment
|
JP5654246B2
(ja)
|
2010-03-03 |
2015-01-14 |
一般社団法人ファルマバレープロジェクト支援機構 |
キナゾリン化合物を有効成分とする医薬組成物
|
TWI516264B
(zh)
|
2010-05-06 |
2016-01-11 |
臺北醫學大學 |
芳香醯喹啉化合物
|
DE102010023949A1
(de)
|
2010-06-16 |
2011-12-22 |
F. Holzer Gmbh |
In-situ Lecithin-Mikroemulsionsgel-Formulierung
|
JP5921535B2
(ja)
|
2010-06-16 |
2016-05-24 |
ディナバックス テクノロジーズ コーポレイション |
Tlr7および/またはtlr9阻害剤を用いる治療の方法
|
WO2011163610A2
(en)
|
2010-06-25 |
2011-12-29 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
US20120252756A1
(en)
|
2010-06-25 |
2012-10-04 |
Coffey Martin J |
Pharmaceutical Compositions and Methods for Treating, Controlling, Ameliorating, or Reversing Conditions of the Eye
|
CN102958930B
(zh)
|
2010-06-28 |
2018-04-27 |
默克专利有限公司 |
作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物
|
BR112012033388A2
(pt)
|
2010-07-02 |
2016-11-22 |
Alcon Res Ltd |
compostos para o tratamento de distúrbios e doenças de segmento posterior
|
WO2012012627A1
(en)
|
2010-07-22 |
2012-01-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of preventing or treating viral infection
|
JP5878172B2
(ja)
|
2010-07-29 |
2016-03-08 |
ラボラトワール フルニエ エスアーエス |
炎症性眼疾患の治療/予防用化合物
|
WO2012014114A1
(en)
|
2010-07-30 |
2012-02-02 |
Ranbaxy Laboratories Limited |
Matrix metalloproteinase inhibitors
|
EP2609084A1
(en)
|
2010-08-27 |
2013-07-03 |
Grünenthal GmbH |
Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
|
WO2012039979A2
(en)
|
2010-09-10 |
2012-03-29 |
The Johns Hopkins University |
Rapid diffusion of large polymeric nanoparticles in the mammalian brain
|
WO2012040499A2
(en)
|
2010-09-22 |
2012-03-29 |
Surface Logix, Inc. |
Metabolic inhibitors
|
SG188644A1
(en)
|
2010-09-24 |
2013-05-31 |
Ranbaxy Lab Ltd |
Matrix metalloproteinase inhibitors
|
CA2812319A1
(en)
|
2010-09-24 |
2012-03-29 |
Ranbaxy Laboratories Limited |
Matrix metalloproteinase inhibitors
|
JP2013538821A
(ja)
|
2010-09-24 |
2013-10-17 |
ランバクシー ラボラトリーズ リミテッド |
マトリックスメタロプロテイナーゼ阻害剤
|
WO2012050985A1
(en)
|
2010-10-13 |
2012-04-19 |
Trustees Of Boston University |
Inhibitors of late sv40 factor (lsf) as cancer chemotherapeutics
|
JP2013543844A
(ja)
|
2010-10-22 |
2013-12-09 |
バインド セラピューティックス インコーポレイテッド |
高分子コポリマーを含む治療用ナノ粒子
|
DE102010050570A1
(de)
|
2010-11-05 |
2012-05-10 |
F. Holzer Gmbh |
Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors
|
AU2011323250B2
(en)
|
2010-11-05 |
2015-11-19 |
The Johns Hopkins University |
Compositions and methods relating to reduced mucoadhesion
|
WO2012064897A2
(en)
|
2010-11-09 |
2012-05-18 |
Yuan Chen |
Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use
|
WO2012071042A1
(en)
|
2010-11-24 |
2012-05-31 |
Government Of The U.S.A. Represented By The Secretary, Dept. Of Health & Human Services |
Compositions and methods for treating or preventing lupus
|
WO2012074980A2
(en)
|
2010-12-01 |
2012-06-07 |
Dara Biosciences, Inc. |
Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives
|
US8648118B2
(en)
*
|
2010-12-17 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
Bicyclic ring system substituted amide functionalised phenols as medicaments
|
AR084433A1
(es)
|
2010-12-22 |
2013-05-15 |
Ironwood Pharmaceuticals Inc |
Inhibidores de la faah y composiciones farmaceuticas que los contienen
|
WO2012088431A1
(en)
|
2010-12-23 |
2012-06-28 |
Ironwood Pharmaceuticals, Inc. |
Faah inhibitors
|
WO2012090177A2
(en)
*
|
2010-12-30 |
2012-07-05 |
Lupin Limited |
Cannabinoid receptor modulators
|
US20140024627A1
(en)
|
2011-01-03 |
2014-01-23 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
|
US8980909B2
(en)
|
2011-01-12 |
2015-03-17 |
Crystal Biopharmaceutical Llc |
HDAC inhibiting derivatives of camptothecin
|
WO2012106534A2
(en)
|
2011-02-02 |
2012-08-09 |
The Regents Of The University Of California |
Hiv integrase inhibitors
|
US9327037B2
(en)
|
2011-02-08 |
2016-05-03 |
The Johns Hopkins University |
Mucus penetrating gene carriers
|
US20120214803A1
(en)
|
2011-02-18 |
2012-08-23 |
Vifor (International) Ag |
Novel Sulfonaminoquinoline Hepcidin Antagonists
|
EP2678052B1
(en)
|
2011-02-24 |
2018-09-26 |
Emory University |
Jab1 blocking compositions for ossification and methods related thereto
|
JP6277121B2
(ja)
|
2011-03-22 |
2018-02-07 |
アドヴィナス・セラピューティックス・リミテッド |
置換された縮合三環式化合物、その組成物および医学的応用
|
US10316371B2
(en)
|
2011-03-29 |
2019-06-11 |
Trana Discovery, Inc. |
Screening methods for identifying specific Staphylococcus aureus inhibitors
|
AU2012242807A1
(en)
|
2011-04-14 |
2013-11-07 |
Allergan, Inc. |
Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
|
US8507686B2
(en)
|
2011-04-14 |
2013-08-13 |
Allergan, Inc. |
Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
|
BR112013026807A2
(pt)
|
2011-04-18 |
2017-01-10 |
Allergan Inc |
derivados de metil amina bicíclicos substituídos como moduladores dos receptores de esfinfgosina-1 fosfato
|
AR086074A1
(es)
|
2011-04-26 |
2013-11-13 |
Genentech Inc |
Composiciones y metodo para tratar enfermedades autoinmunes
|
US8835410B2
(en)
|
2011-05-10 |
2014-09-16 |
Bodor Laboratories, Inc. |
Treatment of eyelid dermatitis
|
TWI632914B
(zh)
|
2011-05-12 |
2018-08-21 |
遠景生物製藥股份有限公司 |
具有類固醇類或非類固醇抗發炎藥之安定的普維酮-碘(Povidone-Iodine)組合物
|
US20140235548A1
(en)
|
2011-05-17 |
2014-08-21 |
Cleave Biosciences, Inc. |
Compositions and methods for jamm protein inhibition
|
WO2012158810A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
WO2012162698A1
(en)
|
2011-05-26 |
2012-11-29 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for the treatment of immune disorders
|
EA201490177A1
(ru)
|
2011-06-29 |
2014-08-29 |
Оцука Фармасьютикал Ко., Лтд. |
Хиназолины как терапевтические соединения и связанные с ними способы их применения
|
WO2013013614A1
(zh)
|
2011-07-28 |
2013-01-31 |
南京英派药业有限公司 |
4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
|
JP5753027B2
(ja)
|
2011-08-22 |
2015-07-22 |
ユー・ディー・シー アイルランド リミテッド |
有機電界発光素子、化合物、並びに該素子を用いた発光装置、表示装置及び照明装置
|
TW202126313A
(zh)
|
2011-09-16 |
2021-07-16 |
美商遠景生物製藥股份有限公司 |
安定之普維酮—碘組成物
|
WO2013061269A1
(en)
|
2011-10-26 |
2013-05-02 |
Micro Labs Limited |
Combinations of loteprednol and olopatadine for the treatment of ocular allergies
|
WO2013067449A1
(en)
|
2011-11-03 |
2013-05-10 |
Taiwan Liposome Company, Ltd. |
Pharmaceutical compositions of hydrophobic camptothecin derivatives
|
WO2013065029A1
(en)
|
2011-11-04 |
2013-05-10 |
Micro Labs Limited |
Fixed dose combination containing moxifloxacin and prednisolone for treatment of ocular infections
|
US20130116279A1
(en)
|
2011-11-07 |
2013-05-09 |
Kalypsys, Inc. |
Bicyclic heteroaryl inhibitors of pde4
|
WO2013070852A2
(en)
|
2011-11-08 |
2013-05-16 |
Emory University |
Compounds and compositions used to epigenetically transform cells and methods related thereto
|
CN103102342B
(zh)
|
2011-11-14 |
2014-10-29 |
广东东阳光药业有限公司 |
氨基喹唑啉类衍生物及其盐和使用方法
|
CN103102345B
(zh)
|
2011-11-14 |
2015-06-03 |
广东东阳光药业有限公司 |
氨基喹唑啉类衍生物及其盐和使用方法
|
AR092289A1
(es)
|
2011-11-14 |
2015-04-15 |
Sunshine Lake Pharma Co Ltd |
Derivados de aminoquinazolina y sus sales y metodos de uso
|
EP2780026B1
(en)
|
2011-11-15 |
2019-10-23 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
CA2859046C
(en)
|
2011-12-14 |
2019-10-22 |
The Johns Hopkins University |
Nanoparticles with enhanced mucosal penetration or decreased inflammation
|
CN103183674B
(zh)
|
2011-12-31 |
2017-09-12 |
江苏先声药业有限公司 |
一类稠杂环衍生物及其应用
|
WO2013118071A1
(en)
|
2012-02-09 |
2013-08-15 |
Glenmark Pharmaceuticals S.A. |
BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
|
CN104520255A
(zh)
|
2012-02-10 |
2015-04-15 |
加利福尼亚大学董事会 |
用于氢化硅烷化的第一排金属基催化剂
|
CN103304572A
(zh)
|
2012-03-09 |
2013-09-18 |
上海医药集团股份有限公司 |
一类3-氰基喹啉类化合物及其药用组合物和应用
|
WO2013158928A2
(en)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
WO2013177367A2
(en)
|
2012-05-23 |
2013-11-28 |
The Johns Hopkins University |
Compounds and methods of use thereof for treating neurodegenerative disorders
|
WO2013179144A2
(en)
|
2012-06-01 |
2013-12-05 |
Oxalys Pharmaceuticals |
Chemical suppressors of neurotoxicity in synucleinopathic diseases
|
CN104583206A
(zh)
|
2012-06-15 |
2015-04-29 |
加利福尼亚大学董事会 |
用于脑癌的新颖治疗剂
|
CN104768946B
(zh)
|
2012-07-20 |
2017-05-03 |
克里弗生物科学公司 |
作为p97复合物的抑制剂的稠合嘧啶
|
CN103804292A
(zh)
|
2012-11-05 |
2014-05-21 |
江苏唐果医药科技有限公司 |
Hdm2和hdmx双重抑制剂3-腈基喹啉衍生物及其制备方法与应用
|
JP6362610B2
(ja)
|
2012-11-08 |
2018-07-25 |
アジオス ファーマシューティカルズ, インコーポレイテッド |
治療用化合物及び組成物並びにpkm2調節剤としてのそれらの使用
|
WO2014074517A1
(en)
|
2012-11-08 |
2014-05-15 |
Emory University |
Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
|
US9701638B2
(en)
|
2012-11-09 |
2017-07-11 |
Rutgers, The State University Of New Jersey |
Therapeutic hydroxyquinolones
|
KR102051910B1
(ko)
|
2012-11-30 |
2019-12-09 |
에스에프씨주식회사 |
중수소 치환된 유기금속 착물 및 이를 포함하는 유기 발광 소자
|
CN103848785B
(zh)
|
2012-12-04 |
2016-07-13 |
上海医药集团股份有限公司 |
一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
|
US20150318498A1
(en)
|
2012-12-21 |
2015-11-05 |
Merck Patent Gmbh |
Metal Complexes
|
US9353122B2
(en)
*
|
2013-02-15 |
2016-05-31 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
KR102084421B1
(ko)
|
2013-02-15 |
2020-03-05 |
에스에프씨주식회사 |
신규한 유기 화합물 및 이를 포함하는 유기 발광 소자
|
ES2831625T3
(es)
|
2013-02-20 |
2021-06-09 |
Kala Pharmaceuticals Inc |
Compuestos terapéuticos y sus usos
|
KR102118013B1
(ko)
|
2013-02-22 |
2020-06-05 |
에스에프씨주식회사 |
신규한 유기 화합물 및 이를 포함하는 유기 발광 소자
|
CN105308031B
(zh)
|
2013-03-04 |
2017-10-13 |
健康科学北方研究所 |
喹啉磺酰基衍生物及其用途
|
WO2014141057A2
(en)
|
2013-03-12 |
2014-09-18 |
Mahesh Kandula |
Compositions and methods for the treatment of cancer
|
KR20150135359A
(ko)
|
2013-03-14 |
2015-12-02 |
컨버진 엘엘씨 |
브로모도메인-함유 단백질의 억제를 위한 방법 및 조성물
|
WO2014141110A2
(en)
|
2013-03-14 |
2014-09-18 |
Curadev Pharma Pvt. Ltd. |
Aminonitriles as kynurenine pathway inhibitors
|
BR112015023948A2
(pt)
|
2013-03-18 |
2017-07-18 |
Genoscience Pharma |
composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
|
EP2994142A4
(en)
|
2013-05-08 |
2017-03-29 |
Colorado Seminary, Which Owns and Operates The University of Denver |
Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
|
CA2912064A1
(en)
|
2013-05-16 |
2014-11-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds for inhibiting drug-resistant strains of hiv-1 integrase
|
JP6419802B2
(ja)
|
2013-10-14 |
2018-11-07 |
メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングMerck Patent GmbH |
電子素子のための材料
|